Additionally, panning with freshly isolated patient-derived malignant plasma cells might further increase the possibility to identify novel antibodies against myeloma cell surface structures with potent anti-tumor activity since at least some antigens, e.g. CD307/FcRH5, might be lost upon cultivation [38]. The gene discussed is FCRL5; the disease is plasma cell myeloma.